Literature DB >> 8101220

Beta 3-adrenoceptors in dog adipose tissue: studies on their involvement in the lipomobilizing effect of catecholamines.

J Galitzky1, M Reverte, C Carpene, M Lafontan, M Berlan.   

Abstract

The existence of beta 3-adrenoceptors in adipose tissue and their involvement in the control of lipolysis was investigated in dog. Selective beta 3-adrenergic agonists (BRL 37344, SR 58611A and CGP 12177) and catecholamines (isoproterenol and norepinephrine) activated lipolysis in isolated adipocytes (order of potency: isoproterenol > BRL 37344 > norepinephrine > CGP 12177 > SR 58611A). The lipolytic effect of 0.05 microM BRL 37344 was antagonized by the nonselective beta-AR antagonists, but the selective beta 1-(CGP 20712A) and beta 2-(ICI 118551) antagonists were ineffective. Infused to conscious dogs, beta 3-adrenergic agonists increased plasma nonesterified fatty acids levels with an order of potency equivalent to that defined in lipolysis. The lipomobilizing effect induced by the administration of an alpha 2-antagonist (0.01 mg/kg RX 821002 i.v.) was suppressed by bupranolol (0.5 mg/kg) or the combination of CGP 20712A and ICI 118551 (0.25 mg/kg each). The effect of 0.05 mg/kg RX 821002 was only partially suppressed by the same beta-antagonist combination, whereas bupranolol totally abolished it. At 0.5 mg/kg, the RX 821002 effect was not modified by beta-antagonists. The lipomobilization due to infusion of catecholamines (0.1, 0.5 or 5 micrograms/kg/min norepinephrine or 5 micrograms/kg/min epinephrine) was always suppressed by bupranolol or the combination of selective beta-antagonists. Thus dog adipocytes express functional beta 3-ARs. Their stimulation induces lipid mobilization. The lipomobilization of exogenously administered catecholamines is due only to the recruitment of beta 1- or beta 2-ARs. However, endogenous catecholamines released after sympathetic nervous system activation could stimulate beta 3-ARs in adipocytes only if a high level of sympathetic nervous system activity is realized.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8101220

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

1.  β(3) Receptors: Role in Cardiometabolic Disorders.

Authors:  Shraddha V Bhadada; Bhoomika M Patel; Anita A Mehta; Ramesh K Goyal
Journal:  Ther Adv Endocrinol Metab       Date:  2011-04       Impact factor: 3.565

2.  Beta 3-adrenoceptor stimulation induces vasorelaxation mediated essentially by endothelium-derived nitric oxide in rat thoracic aorta.

Authors:  J N Trochu; V Leblais; Y Rautureau; F Bévérelli; H Le Marec; A Berdeaux; C Gauthier
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

3.  Functional beta3-adrenoceptor in the human heart.

Authors:  C Gauthier; G Tavernier; F Charpentier; D Langin; H Le Marec
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

4.  Characterization of beta 1- and beta 3-adrenoceptors in intact brown adipocytes of the rat.

Authors:  F D'Allaire; C Atgié; P Mauriège; P M Simard; L J Bukowiecki
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

5.  The β3 Adrenergic Receptor Antagonist L-748,337 Attenuates Dobutamine-Induced Cardiac Inefficiency While Preserving Inotropy in Anesthetized Pigs.

Authors:  Lars Rødland; Leif Rønning; Anders Benjamin Kildal; Ole-Jakob How
Journal:  J Cardiovasc Pharmacol Ther       Date:  2021-09-23       Impact factor: 2.457

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.